Mixed
Amantadine: improve symptoms or function in MS (type not specified)
MS (type not specified) · Fatigue / wakefulness
Controlled trials disagree.
- Trials
- 4
- Running now
- 0
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 744
Deciding trials (phase 3): 1 met, 1 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairmentdecides the statusMet main goal
Phase 3 · 2018 · Placebo-controlled · MSFT-NCT03436199
Phase 3 · 2017 · Placebo-controlled · MSFT-NCT03185065
The estimated mean values of MFIS total scores at baseline and the maximal tolerated dose were as follows: 51·3 (95% CI 49·0-53·6) at baseline, 40·6 (38·2-43·1) with placebo, 41·3 (38·8-43·7) with amantadine, 39·0 (36·6-41·4) with modafinil, and 38·6 (36·2-41·0) with methylphenidate (p=0·20 for the overall medication effect in the linear mixed-effect regression model).
Read by software from the paper's abstract
Other linked trials: 2
These linked trials do not set the status.
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Results pending to Mixed
- 2026-10-27First listed as Results pending
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error